Why Inogen, Inc.’s (INGN) Stock Is Down 6.06%
As of Tuesday, June 30, Inogen, Inc.’s INGN share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Commentary & Analysis
Why Inogen, Inc.’s (INGN) Stock Is Up 5.45%
As of Tuesday, June 09, Inogen, Inc.’s INGN share price has surged by 5.45%, which has investors questioning if this is right time to sell.Michael Rose
Why Inogen, Inc.’s (INGN) Stock Is Up 7.58%
As of Thursday, June 04, Inogen, Inc.’s INGN share price has surged by 7.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Inogen, Inc.’s (INGN) Stock Is Down 5.59%
As of Friday, May 15, Inogen, Inc.’s INGN share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Inogen, Inc.’s (INGN) Stock Is Down 7.12%
As of Monday, May 11, Inogen, Inc.’s INGN share price has dipped by 7.12%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | INGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $173.8 | $334.8 | 26% |
|
| Shares Out (Mil) | 27.3 | 41.7 | 35% |
|
| Institutional Ownership | 96.1% | 77.3% | 69% |
|
| Float (Mil) | 23.7 | 34.7 | 32% |
|
| Beta | 1.65 | 0.86 | 86% |
|
| Avg Daily Volume (000s) | 191 | 266 | 44% |
|
| Price Change (52-week) |
(2.7%) | 60.7% | 43% |
|
| Growth | INGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.5% | 11.8% | 25% |
|
| Net Income (5yr) | (31.4%) | (5.8%) | 13% |
|
| EPS (5yr) | (26.1%) | 10.7% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (22.4%) | (16.1%) | 29% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.060) | ($0.370) | ($0.260) | |
| Month Ago EPS | ($0.060) | ($0.370) | ($0.260) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.030) | ($0.520) | ($0.310) | |
| Year/Year Chg | (80.3%) | (57.0%) | (89.5%) | |
| Financials | INGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $352 | $152 | 38% |
|
| Net Income (TTM) (Mil) | ($25) | ($11) | 22% |
|
| EPS (TTM) | ($0.917) | ($0.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($2) | 30% |
|
| Net Cash Flow (TTM) (Mil) | ($28) | $1 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $22 | 30% |
|
| Enterprise Value (Q1) (Mil) | $86 | $304 | 20% |
|
| Valuation | INGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.96 | 2.88 | 21% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | INGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.3% | 59.1% | 56% |
|
| Net Margin | (7.1%) | (7.7%) | 23% |
|
| ROA | (8.4%) | (13.7%) | 27% |
|
| ROE | (13.1%) | (15.9%) | 26% |
|
| Liabilities to Assets | 36.0% | 44.9% | 27% |
|
| F-Score | 5 | 4 | 51% |
|
Inogen, Inc. did not pass any screens on 7/30/2026.
